Loading company…
Riskpilot
← Back to search
Sign in
Get full access
KLYV THERAPEUTICS AS
AS
Active
Org 832316032
Gaustadalléen 21, 0349 Oslo
Research and experimental development on natural sciences and engineering · NACE 7210
Est. 2023
0 employees
Watchlist
Share
Overview
Financials
People & ownership
Related companies
Revenue 2024
NOK 746K
EBITDA margin
-0.7%
-244500% vs 2023
Equity ratio
64.2%
Financial strength
Net profit 2024
NOK 148
+7500% vs 2023
EBITDA — year on year
NOK millions
0M
-0M
-1M
-1M
-1M
0M
2023
0M
0%
2024
Key figures
Annual report 2024
Revenue
NOK 746K
—
EBITDA
NOK -5K
-244500%
Net profit
NOK 148
+7500%
Total assets
NOK 934K
+890%
Equity
NOK 600K
+536%
Employees
0
—
Company information
Legal name
KLYV THERAPEUTICS AS
Org number
832316032
Legal form
Aksjeselskap
NACE code
7210 · Research and experimental development on natural sciences and engineering
Founded
24. oktober 2023
Share capital
NOK 121 816
Employees
0
VAT registered
Yes
Audit selected
No
Last report
2024-12-31
Financial year
January – December
Company purpose
Utvikle og investere i legemidler, legemiddelkandidater, hjelpemidler, verktøy og metoder for pasientbehandling og persontilpasset medisin.
Contact
Address
Gaustadalléen 21, 0349 Oslo
Risika for professionals
Risika provides regulated workflow tools for finance, procurement and compliance teams that need monitoring, alerts and an API.
Visit risika.com
Explore
Companies in Research and experimental development on natural sciences and engineering
Companies in Oslo
All Norway companies
Revenue
NOK millions
0M
0M
1M
1M
1M
0M
2023
1M
2024
EBITDA
NOK millions
0M
0M
1M
1M
1M
0M
2023
0M
2024
Income statement
NOK thousands
Item
2023
2024
Revenue
0
746
Staff expenses
−0
−0
EBITDA
−0
−5
Depreciation & amort.
−0
−0
EBIT
−0
−5
Net financials
0
5
Profit before tax
−0
0
Tax
−0
−0
Net profit
−0
0
Balance sheet
NOK thousands
Item
2023
2024
Total assets
94
934
Equity
94
600
Long-term debt
0
0
Short-term debt
0
334
Total debt
0
334
Financial ratios
5-year trend
EBITDA margin
-0.7%
This company
15.8%
Market median
-104% vs market
2023
2024
Equity ratio
64.2%
This company
38.2%
Market median
+68% vs market
2023
2024
Return on equity
0.0%
This company
18.4%
Market median
-100% vs market
2023
2024
Net profit margin
0.0%
This company
8.1%
Market median
-100% vs market
2023
2024
Asset turnover
0.80×
This company
1.12×
Market median
-29% vs market
2023
2024
Debt / equity
0.56×
This company
0.62×
Market median
+10% vs market
2023
2024
Annual reports & filings
Annual report 2024
Filed via Brønnøysundsregistrene · Period 2024-01-01 – 2024-12-31
View
PDF
Annual report 2023
Filed via Brønnøysundsregistrene · Period 2023-08-30 – 2023-12-31
View
PDF
Management
Actively employed in the business
Name
Role
Member since
Current (1)
MV
Maria Vistnes
Chief Executive Officer
Chief Executive Officer
2023
Board of directors
Non-executive oversight
Name
Role
Member since
Current (3)
BL
Beret Luise Sundet
Board of Directors
2024
AB
Andreas Berg
Chairman
2023
TS
Torkild Stenbock
Board of Directors
2024
Shareholders
As of last annual report
Shareholder
Type
Ownership
Votes
Since
Springheart Holding As
Company
78.64%
78.64%
2024
Tailormade Invest As
Company
20.12%
20.12%
2024
Beneficial ownership (UBO) data access is restricted in Denmark as of September 2025 per the EU 6th AML Directive.
Learn more
.
Company hierarchy
Springheart Holding As
KLYV THERAPEUTICS AS
(this company)
Board network connections
Board members of KLYV THERAPEUTICS AS also hold positions in
0
other companies.
Person
Role here
Other companies
Maria Vistnes
Chief Executive Officer
0 companies
Beret Luise Sundet
Board of Directors
0 companies
Andreas Berg
Chairman
0 companies
Torkild Stenbock
Board of Directors
0 companies